上市公司資料
 
榮昌生物製藥(煙台)股份有限公司 股票代號:  09995
REMEGEN CO., LTD. 集團網址: http://www.remegen.com
損益表
  2023/12
RMB($)
變動 2022/12
RMB($)
2021/12
RMB($)
營業額1,076,130,00040.162%767,775,0001,423,902,000
經營溢利/(虧損)(1,511,184,000)--(998,830,000)276,258,000
特殊項目--------
攤佔聯營公司及共同控制公司溢利/(虧損)(45,000)--00
稅前溢利/(虧損)(1,511,229,000)--(998,830,000)276,258,000
稅項0--00
少數股東權益0--00
股東應佔溢利/(虧損)(1,511,229,000)--(998,830,000)276,258,000
 
淨利息收入/(支出)5,052,000-90.779%54,786,00038,025,000
折舊與攤銷240,794,00028.903%186,803,000120,797,000
董事酬金55,852,000-2.739%57,425,00021,470,000
 
每股盈利/(虧損)(仙)(280.000)--(188.000)57.000
每股派息(仙)0.000--0.0000.000
 
派息比率(%)------0.000%
每股帳面資產淨值($)6.315-30.983%9.1517.036
主要財務比率
  2023/12
RMB($)
變動 2022/12
RMB($)
2021/12
RMB($)
經營邊際利潤率(%)(140.428)%--(130.094)%19.401%
利息盈利率(x)------52.899
資產回報率(%)(26.170)%--(19.623)%6.675%
股東資金回報率(%)(35.907)%--(23.706)%7.847%

 

Copyright © 2025 ET Net Limited. All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.